Home LiteratureArticle Details
PMID: 12408237 Published · ppublish English Journal Article Review

Mechanistic approaches to Parkinson's disease pathogenesis.

Brain pathology (Zurich, Switzerland) ·Vol. 12 ·No. 4 ·2002-10-00 ·Pages 499-510

Betarbet R, Sherer TB, Di Monte DA, Greenamyre JT

Abstract

Parkinson's disease (PD) is a progressive neurological disorder marked by nigrostriatal dopaminergic degeneration and development of cytoplasmic proteinaceous aggregates known as Lewy bodies. Although the pathogenic mechanisms responsible for PD are not completely understood, many clues have come from biochemical, epidemiological, and genetic studies. Mutations in certain genes found in rare, familial cases of PD, such as alpha-synuclein and parkin, suggest a role for the ubiquitin-proteosome system and aberrant protein aggregation. Biochemical analyses have implicated mitochondrial dysfunction in PD. Epidemiological and animal model studies point to a role for environmental toxins, some of which are mitochondrial inhibitors. Mitochondrial dysfunction, resulting from either genetic defects, environmental exposures or an interaction between the two, may cause alpha-synuclein aggregation or neurodegeneration through oxidative stress or excitotoxicity. A better understanding of the mechanisms underlying PD should reveal novel therapeutic targets.

MeSH Terms
Animals Brain/drug effects,metabolism,physiopathology Environmental Exposure Humans Mitochondria/drug effects,metabolism,pathology Mutation/genetics Nerve Tissue Proteins/drug effects,genetics,metabolism Neurons/drug effects,metabolism,pathology Neurotoxins/toxicity Oxidative Stress/drug effects,physiology Parkinson Disease/etiology,genetics,metabolism Synucleins alpha-Synuclein
Chemicals
Nerve Tissue Proteins Neurotoxins SNCA protein, human Synucleins alpha-Synuclein
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Betarbet Ranjita
Center for Neurodegenerative Disease and Department of Neurology, Emory University, Atlanta, GA 30322, USA. rbetarb@emory.edu
Sherer Todd B
Di Monte Donato A
Greenamyre J Timothy
References (101)
101 references, click to expand
  1. Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors.
    J Biol Chem. 2002 Feb 15;277(7):5411-7 PMID: 11724769
  2. Nuclear magnetic relaxation dispersion profiles of substantia nigra pars compacta in Parkinson's disease patients are consistent with protein aggregation.
    Neurochem Int. 2000 Oct;37(4):331-6 PMID: 10825573
  3. Parkinson's disease: a case-control study of occupational and environmental risk factors.
    Am J Ind Med. 1990;17(3):349-55 PMID: 2305814
  4. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.
    Science. 1997 Jun 27;276(5321):2045-7 PMID: 9197268
  5. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds.
    J Neurochem. 1993 Oct;61(4):1191-206 PMID: 8376979
  6. Pathoanatomy of Parkinson's disease.
    J Neurol. 2000 Apr;247 Suppl 2:II3-10 PMID: 10991663
  7. The ubiquitin pathway in Parkinson's disease.
    Nature. 1998 Oct 1;395(6701):451-2 PMID: 9774100
  8. The functional anatomy of basal ganglia disorders.
    Trends Neurosci. 1989 Oct;12(10):366-75 PMID: 2479133
  9. Subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease.
    Ann Neurol. 2001 Apr;49(4):525-9 PMID: 11310632
  10. Evidence for generation of oxidative stress in brain by MPTP: in vitro and in vivo studies in mice.
    Brain Res. 1997 Feb 21;749(1):44-52 PMID: 9070626
  11. Mitochondrial respiratory chain activity in skeletal muscle from patients with Parkinson's disease.
    Neurology. 1993 Nov;43(11):2258-62 PMID: 8232939
  12. Genetic and environmental risk factors for Parkinson's disease in a Chinese population.
    J Neurol Neurosurg Psychiatry. 1998 Nov;65(5):781-4 PMID: 9810958
  13. The pharmacology of (-)deprenyl.
    J Neural Transm Suppl. 1986;22:75-89 PMID: 3097262
  14. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease.
    Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2696-701 PMID: 8610103
  15. Oxidative mechanisms in nigral cell death in Parkinson's disease.
    Mov Disord. 1998;13 Suppl 1:24-34 PMID: 9613715
  16. Novel free radical spin traps protect against malonate and MPTP neurotoxicity.
    Exp Neurol. 1999 May;157(1):120-6 PMID: 10222114
  17. Vitamin E attenuates the toxic effects of 6-hydroxydopamine on free radical scavenging systems in rat brain.
    Brain Res Bull. 1992 Nov;29(5):699-701 PMID: 1422867
  18. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease.
    J Neurochem. 1989 Feb;52(2):381-9 PMID: 2911023
  19. Environmental risk factors and Parkinson's disease: a metaanalysis.
    Environ Res. 2001 Jun;86(2):122-7 PMID: 11437458
  20. Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement.
    J Neurochem. 1992 Feb;58(2):786-9 PMID: 1729421
  21. Occupational metal exposures and the risk of Parkinson's disease.
    Neuroepidemiology. 1999;18(6):303-8 PMID: 10545782
  22. Parkinson's disease, pesticides, and glutathione transferase polymorphisms.
    Lancet. 1998 Oct 24;352(9137):1344-6 PMID: 9802272
  23. Neural mechanisms in disorders of movement.
    Comp Biochem Physiol A Comp Physiol. 1989;93(1):141-9 PMID: 2568216
  24. Nigral and extranigral pathology in Parkinson's disease.
    J Neural Transm Suppl. 1995;46:15-31 PMID: 8821039
  25. Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies.
    J Biol Chem. 2000 Jun 16;275(24):18344-9 PMID: 10747881
  26. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein.
    J Biol Chem. 2002 Jan 18;277(3):1641-4 PMID: 11707429
  27. Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice.
    Neurosci Lett. 2000 Mar 10;281(2-3):167-70 PMID: 10704769
  28. Degradation of alpha-synuclein by proteasome.
    J Biol Chem. 1999 Nov 26;274(48):33855-8 PMID: 10567343
  29. Origin and functional consequences of the complex I defect in Parkinson's disease.
    Ann Neurol. 1996 Oct;40(4):663-71 PMID: 8871587
  30. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly.
    Am J Physiol. 1996 Nov;271(5 Pt 1):C1424-37 PMID: 8944624
  31. Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation.
    J Biol Chem. 1998 Oct 9;273(41):26292-4 PMID: 9756856
  32. Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity. Implications for Parkinson's disease.
    J Biol Chem. 2000 Aug 25;275(34):26096-101 PMID: 10846169
  33. Dynamic association of proteasomal machinery with the centrosome.
    J Cell Biol. 1999 May 3;145(3):481-90 PMID: 10225950
  34. Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: behavioural and immunohistochemical studies.
    Eur J Neurosci. 1996 Jul;8(7):1408-14 PMID: 8758948
  35. Primate models of movement disorders of basal ganglia origin.
    Trends Neurosci. 1990 Jul;13(7):281-5 PMID: 1695404
  36. Mitochondrial function in Parkinson's disease.
    Lancet. 1989 Jul 1;2(8653):49 PMID: 2567823
  37. alpha-synuclein promotes mitochondrial deficit and oxidative stress.
    Am J Pathol. 2000 Aug;157(2):401-10 PMID: 10934145
  38. Abnormalities of the electron transport chain in idiopathic Parkinson's disease.
    Ann Neurol. 1989 Dec;26(6):719-23 PMID: 2557792
  39. Complex I inhibitors as insecticides and acaricides.
    Biochim Biophys Acta. 1998 May 6;1364(2):287-96 PMID: 9593947
  40. Mechanisms of action of 6-hydroxydopamine.
    Biochem Pharmacol. 1975 Jan 1;24(1):1-8 PMID: 1092302
  41. Neuropathology in mice expressing human alpha-synuclein.
    J Neurosci. 2000 Aug 15;20(16):6021-9 PMID: 10934251
  42. Alpha-synuclein in Lewy bodies.
    Nature. 1997 Aug 28;388(6645):839-40 PMID: 9278044
  43. Inhibitors of NADH-ubiquinone reductase: an overview.
    Biochim Biophys Acta. 1998 May 6;1364(2):222-35 PMID: 9593904
  44. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living.
    Neurology. 1998 May;50(5):1346-50 PMID: 9595985
  45. 1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles.
    Biochem Biophys Res Commun. 1990 Aug 16;170(3):1049-55 PMID: 2167668
  46. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity.
    Proc Natl Acad Sci U S A. 1985 Apr;82(7):2173-7 PMID: 3872460
  47. Point mutations (Thr240Arg and Gln311Stop) [correction of Thr240Arg and Ala311Stop] in the Parkin gene.
    Biochem Biophys Res Commun. 1998 Aug 28;249(3):754-8 PMID: 9731209
  48. Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine.
    Lancet. 1985 Nov 30;2(8466):1213-6 PMID: 2866293
  49. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders.
    Science. 2000 Feb 18;287(5456):1265-9 PMID: 10678833
  50. Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease.
    Brain. 1992 Apr;115 ( Pt 2):333-42 PMID: 1606472
  51. Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: behavioral and biochemical evidence.
    Brain Res. 1989 Jan 2;476(1):10-5 PMID: 2492442
  52. Protein nitration in Parkinson's disease.
    J Neuropathol Exp Neurol. 1998 Apr;57(4):338-42 PMID: 9600227
  53. Proteasomal function is impaired in substantia nigra in Parkinson's disease.
    Neurosci Lett. 2001 Jan 19;297(3):191-4 PMID: 11137760
  54. Alternative excitotoxic hypotheses.
    Neurology. 1992 Apr;42(4):733-8 PMID: 1314341
  55. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions.
    Science. 2000 Nov 3;290(5493):985-9 PMID: 11062131
  56. Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy.
    J Neurol Sci. 1994 Aug;125(1):95-101 PMID: 7964895
  57. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP.
    J Neurochem. 2000 Feb;74(2):721-9 PMID: 10646524
  58. Mitochondrial complex I deficiency in Parkinson's disease.
    Lancet. 1989 Jun 3;1(8649):1269 PMID: 2566813
  59. Parkinson's disease: a test of the multifactorial etiologic hypothesis.
    Neurology. 1993 Jun;43(6):1173-80 PMID: 8170564
  60. Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease.
    Ann Neurol. 1998 Aug;44(2):177-86 PMID: 9708539
  61. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease.
    J Neurochem. 1997 Sep;69(3):1326-9 PMID: 9282961
  62. Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity.
    Hum Mol Genet. 2000 Nov 1;9(18):2683-9 PMID: 11063727
  63. Mitochondrial oxidative phosphorylation defects in Parkinson's disease.
    Ann Neurol. 1991 Sep;30(3):332-9 PMID: 1952821
  64. Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation.
    Neuroscience. 2000;97(2):279-84 PMID: 10799759
  65. Aggresomes, inclusion bodies and protein aggregation.
    Trends Cell Biol. 2000 Dec;10(12):524-30 PMID: 11121744
  66. Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay.
    J Neurochem. 1998 Jan;70(1):268-75 PMID: 9422371
  67. Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss.
    Brain Res. 1999 Mar 27;823(1-2):1-10 PMID: 10095006
  68. Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease.
    J Neural Transm Gen Sect. 1993;91(2-3):255-69 PMID: 8099800
  69. The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease.
    J Neurosci. 2000 Dec 15;20(24):9207-14 PMID: 11124998
  70. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia.
    Ann Neurol. 1994 Sep;36(3):348-55 PMID: 8080242
  71. Excitatory amino acids and the basal ganglia: implications for the therapy of Parkinson's disease.
    Trends Neurosci. 1989 Aug;12(8):285-6 PMID: 2475945
  72. The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity.
    J Biol Chem. 2000 Dec 8;275(49):38581-8 PMID: 10969076
  73. Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria.
    Biochem J. 1980 Nov 1;191(2):421-7 PMID: 6263247
  74. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct.
    Science. 2001 Nov 9;294(5545):1346-9 PMID: 11701929
  75. Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity.
    Exp Neurol. 1995 Apr;132(2):279-83 PMID: 7789466
  76. A meta-analysis of Parkinson's disease and exposure to pesticides.
    Neurotoxicology. 2000 Aug;21(4):435-40 PMID: 11022853
  77. Homozygous deletions in parkin gene in European and North African families with autosomal recessive juvenile parkinsonism. The European Consortium on Genetic Susceptibility in Parkinson's Disease and the French Parkinson's Disease Genetics Study Group.
    Lancet. 1998 Oct 24;352(9137):1355-6 PMID: 9802278
  78. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism.
    Nature. 1998 Apr 9;392(6676):605-8 PMID: 9560156
  79. Follow-up study of early-life protective and risk factors in Parkinson's disease.
    Mov Disord. 1990;5(1):66-70 PMID: 2296261
  80. Free radical-generated neurotoxicity of 6-hydroxydopamine.
    J Neurochem. 1995 Apr;64(4):1703-7 PMID: 7891098
  81. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage.
    J Neurosci. 2002 Aug 15;22(16):7006-15 PMID: 12177198
  82. Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form.
    J Biol Chem. 2002 Jan 4;277(1):671-8 PMID: 11679584
  83. Pesticides directly accelerate the rate of alpha-synuclein fibril formation: a possible factor in Parkinson's disease.
    FEBS Lett. 2001 Jul 6;500(3):105-8 PMID: 11445065
  84. Maneb enhances MPTP neurotoxicity in mice.
    Res Commun Chem Pathol Pharmacol. 1989 Oct;66(1):167-70 PMID: 2616897
  85. Glutamate induces the production of reactive oxygen species in cultured forebrain neurons following NMDA receptor activation.
    J Neurosci. 1995 May;15(5 Pt 1):3318-27 PMID: 7751912
  86. Failure of the ubiquitin-proteasome system in Parkinson's disease.
    Nat Rev Neurosci. 2001 Aug;2(8):589-94 PMID: 11484002
  87. Environmental risk factors and Parkinson's disease: a case-control study in Taiwan.
    Neurology. 1997 Jun;48(6):1583-8 PMID: 9191770
  88. Sensitization of neuronal cells to oxidative stress with mutated human alpha-synuclein.
    J Neurochem. 2000 Dec;75(6):2546-54 PMID: 11080208
  89. Mitochondrial dysfunction in Parkinson's disease.
    Ann Neurol. 1998 Sep;44(3 Suppl 1):S99-109 PMID: 9749580
  90. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis.
    Science. 1983 Feb 25;219(4587):979-80 PMID: 6823561
  91. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.
    Nat Med. 1998 Nov;4(11):1318-20 PMID: 9809558
  92. Lewy bodies and parkinsonism in families with parkin mutations.
    Ann Neurol. 2001 Sep;50(3):293-300 PMID: 11558785
  93. Interaction of alpha-phenyl-N-tert-butyl nitrone and alternative electron acceptors with complex I indicates a substrate reduction site upstream from the rotenone binding site.
    J Neurochem. 1998 Dec;71(6):2549-57 PMID: 9832155
  94. Glutamate-induced neuron death requires mitochondrial calcium uptake.
    Nat Neurosci. 1998 Sep;1(5):366-73 PMID: 10196525
  95. Aggresomes: a cellular response to misfolded proteins.
    J Cell Biol. 1998 Dec 28;143(7):1883-98 PMID: 9864362
  96. Bioenergetics and glutamate excitotoxicity.
    Prog Neurobiol. 1996 Apr;48(6):613-34 PMID: 8809910
  97. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.
    Life Sci. 1985 Jul 1;36(26):2503-8 PMID: 2861548
  98. Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease.
    Biochim Biophys Acta. 1997 Nov 28;1362(1):77-86 PMID: 9434102
  99. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase.
    Nat Genet. 2000 Jul;25(3):302-5 PMID: 10888878
  100. Chronic systemic pesticide exposure reproduces features of Parkinson's disease.
    Nat Neurosci. 2000 Dec;3(12):1301-6 PMID: 11100151
  101. A Drosophila model of Parkinson's disease.
    Nature. 2000 Mar 23;404(6776):394-8 PMID: 10746727
Article Info
Journal
Brain pathology (Zurich, Switzerland)
Abbr.
Brain Pathol
ISSN
1015-6305
Published
2002-10-00
Pages
499-510
Language
English
Region
Switzerland
NLM ID
9216781
PMCID
PMC8095781
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com